Amarin shares fall 10% as patent wrangling continues, but analysts remain confident
This article was originally published in Scrip
Executive Summary
Shares in Irish biotech Amarin fell nearly 10% on 2 March, as the US Patent and Trademark Office (PTO) issued yet another non-final rejection for one of Amarin's 16 patent applications. The company filed a note with the SEC highlighting its continuing struggle to gain use patents for its lead candidate AMR101, which it has filed in the US as a treatment for patients with very high triglycerides.